Cargando…

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure

BACKGROUND: Valproic acid (VPA) is a clinically used antiepileptic drug, but it is associated with a significant risk of a low verbal intelligence quotient (IQ) score, attention-deficit hyperactivity disorder and autism spectrum disorder in children when it is administered during pregnancy. Prenatal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishihara, Yasuhiro, Honda, Tatsuya, Ishihara, Nami, Namba, Kaede, Taketoshi, Makiko, Tominaga, Yoko, Tsuji, Mayumi, Vogel, Christoph F. A., Yamazaki, Takeshi, Itoh, Kouichi, Tominaga, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335995/ https://www.ncbi.nlm.nih.gov/pubmed/35906621 http://dx.doi.org/10.1186/s12974-022-02559-y

Ejemplares similares

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Overall Assay of Neuronal Signal Propagation Pattern With Long-Term Potentiation (LTP) in Hippocampal Slices From the CA1 Area With Fast Voltage-Sensitive Dye Imaging
por: Tominaga, Yoko, et al.
Publicado: (2018)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

FosL1 Is a Novel Target of Levetiracetam for Suppressing the Microglial Inflammatory Reaction
por: Niidome, Kouji, et al.
Publicado: (2021)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

Assessing seizure liability in vitro with voltage-sensitive dye imaging in mouse hippocampal slices
por: Utsumi, Yuichi, et al.
Publicado: (2023)

Potentiation of 17β-estradiol synthesis in the brain and elongation of seizure latency through dietary supplementation with docosahexaenoic acid
por: Ishihara, Yasuhiro, et al.
Publicado: (2017)

Neuroprotective activation of astrocytes by methylmercury exposure in the inferior colliculus
por: Ishihara, Yasuhiro, et al.
Publicado: (2019)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Polycyclic aromatic hydrocarbons in urban particle matter exacerbate movement disorder after ischemic stroke via potentiation of neuroinflammation
por: Tanaka, Miki, et al.
Publicado: (2023)

Distinct Defects in Synaptic Differentiation of Neocortical Neurons in Response to Prenatal Valproate Exposure
por: Iijima, Yoko, et al.
Publicado: (2016)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Microglial inflammatory reactions regulated by oxidative stress
por: Ishihara, Yasuhiro, et al.
Publicado: (2023)

Involvement of reactive oxygen species derived from mitochondria in neuronal injury elicited by methylmercury
por: Ishihara, Yasuhiro, et al.
Publicado: (2016)

Comprehensive Enzymatic Analysis of the Cellulolytic System in Digestive Fluid of the Sea Hare Aplysia kurodai. Efficient Glucose Release from Sea Lettuce by Synergistic Action of 45 kDa Endoglucanase and 210 kDa ß-Glucosidase
por: Tsuji, Akihiko, et al.
Publicado: (2013)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Altered cortical thickness following prenatal sodium valproate exposure
por: Wood, Amanda G, et al.
Publicado: (2014)

Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
por: Huber-Mollema, Yfke, et al.
Publicado: (2020)

Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells
por: Zhuang, Yuan, et al.
Publicado: (2021)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

Baller-Gerold syndrome: Further evidence for association with prenatal exposure to valproate
por: lype, Mary, et al.
Publicado: (2008)

Prenatal sonographic diagnosis of fetal valproate syndrome: a case report
por: Kikuchi, Norihiko, et al.
Publicado: (2016)

Disrupted Social Hierarchy in Prenatally Valproate-Exposed Autistic-Like Rats
por: Pelsőczi, Péter, et al.
Publicado: (2020)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
por: Jiang, Xiaowei, et al.
Publicado: (2015)

Involvement of the Microglial Aryl Hydrocarbon Receptor in Neuroinflammation and Vasogenic Edema after Ischemic Stroke
por: Tanaka, Miki, et al.
Publicado: (2021)

Association between bisphenol A diglycidyl ether-specific IgG in serum and food sensitization in young children
por: Tsuji, Mayumi, et al.
Publicado: (2018)

Effects of Atomoxetine on Hyper-Locomotive Activity of the Prenatally Valproate-Exposed Rat Offspring
por: Choi, Chang Soon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ihl33uek4tmenkl9p9uiktab5l